Molecular Aspects of the Functioning of Pathogenic Bacteria Biofilm Based on Quorum Sensing (QS) Signal-Response System and Innovative Non-Antibiotic Strategies for Their Elimination

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(5), P. 2655 - 2655

Published: Feb. 24, 2024

One of the key mechanisms enabling bacterial cells to create biofilms and regulate crucial life functions in a global highly synchronized way is communication system called quorum sensing (QS). QS cell-to-cell process that depends on population density mediated by small signalling molecules autoinducers (AIs). In bacteria, controls biofilm formation through regulation gene expression involved extracellular polymeric matrix (EPS) synthesis, virulence factor production, stress tolerance metabolic adaptation. Forming one antimicrobial resistance (AMR). A common feature human pathogens ability form biofilm, which poses serious medical issue due their high susceptibility traditional antibiotics. Because associated with formation, there belief inhibition activity quenching (QQ) may provide alternative therapeutic methods for treating microbial infections. This review summarises recent progress research, focusing biofilms, especially those formed pathogenic become resistant antibiotic treatment. Subsequently, potential approach highlighting innovative non-antibiotic strategies control AMR bacteria has been discussed.

Language: Английский

---

Therapeutic Antibodies in Medicine

Molecules, Journal Year: 2023, Volume and Issue: 28(18), P. 6438 - 6438

Published: Sept. 5, 2023

Antibody engineering has developed into a wide-reaching field, impacting multitude of industries, most notably healthcare and diagnostics. The seminal work on developing the first monoclonal antibody four decades ago witnessed exponential growth in last 10–15 years, where regulators have approved antibodies as therapeutics for several diagnostic applications, including remarkable attention it garnered during pandemic. In recent become fastest-growing class biological drugs treatment wide range diseases, from cancer to autoimmune conditions. This review discusses field therapeutic stands today. It summarizes outlines clinical relevance application treating landscape diseases different disciplines medicine. nomenclature, various approaches therapies, evolution therapeutics. also risk profile adverse immune reactions associated with sheds light future applications perspectives drug discovery.

Language: Английский

---

De novo generation of SARS-CoV-2 antibody CDRH3 with a pre-trained generative large language model

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: Aug. 10, 2024

Artificial Intelligence (AI) techniques have made great advances in assisting antibody design. However, design still heavily relies on isolating antigen-specific antibodies from serum, which is a resource-intensive and time-consuming process. To address this issue, we propose Pre-trained Antibody generative large Language Model (PALM-H3) for the de novo generation of artificial heavy chain complementarity-determining region 3 (CDRH3) with desired antigen-binding specificity, reducing reliance natural antibodies. We also build high-precision model antigen-antibody binder (A2binder) that pairs antigen epitope sequences to predict binding specificity affinity. PALM-H3-generated exhibit ability SARS-CoV-2 antigens, including emerging XBB variant, as confirmed through in-silico analysis in-vitro assays. The assays validate achieve high affinity potent neutralization capability against spike proteins wild-type, Alpha, Delta, variant. Meanwhile, A2binder demonstrates exceptional predictive performance various epitopes variants. Furthermore, by incorporating attention mechanism inherent Roformer architecture into PALM-H3 model, improve its interpretability, providing crucial insights fundamental principles

Language: Английский

---

A High Threshold of Biotherapeutic Aggregate Numbers is Needed to Induce an Immunogenic Response In Vitro, In Vivo, and in the Clinic

Pharmaceutical Research, Journal Year: 2024, Volume and Issue: 41(4), P. 651 - 672

Published: March 22, 2024

Language: Английский

---

The use of proteins and peptides-based therapy in managing and preventing pathogenic viruses

International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: 270, P. 132254 - 132254

Published: May 9, 2024

Language: Английский

---

Whole-canine neutralizing antibodies generated by single B cell antibody technology elicit therapeutic protection against canine distemper virus infection

Veterinary Microbiology, Journal Year: 2025, Volume and Issue: unknown, P. 110412 - 110412

Published: Jan. 1, 2025

Language: Английский

---

Anionic lipids direct efficient microfluidic encapsulation of stable and functionally active proteins in lipid nanoparticles

Communications Materials, Journal Year: 2025, Volume and Issue: 6(1)

Published: Feb. 22, 2025

Language: Английский

---

Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges

Molecular Biotechnology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 2, 2024

Language: Английский

---

Monoclonal antibodies: From magic bullet to precision weapon

Molecular Biomedicine, Journal Year: 2024, Volume and Issue: 5(1)

Published: Oct. 11, 2024

Monoclonal antibodies (mAbs) are used to prevent, detect, and treat a broad spectrum of non-communicable communicable diseases. Over the past few years, market for mAbs has grown exponentially with an expected compound annual growth rate (CAGR) 11.07% from 2024 (237.64 billion USD estimated at end 2023) 2033 (679.03 by 2033). Ever since advent hybridoma technology introduced in 1975, antibody-based therapeutics were realized using murine which further progressed into humanized fully human antibodies, reducing risk immunogenicity. Some benefits over conventional drugs include drastic reduction chances adverse reactions, interactions between drugs, targeting specific proteins. While very efficient, their higher production costs impede process commercialization. However, cost factor been improved developing biosimilar as affordable versions therapeutic antibodies. Along recent advancements innovations antibody engineering have helped will furtherly help design bio-better efficacy than ones. These novel mAb-based set revolutionize existing drug therapies wide diseases, thereby meeting several unmet medical needs. This review provides comprehensive insights current fundamental landscape development applications key factors influencing future projections, advancement, incorporation such promising immunotherapeutic candidates confrontation approach against list rationalistic mentioning any limitations facing this field.

Language: Английский

---

New Senolysis Approach via Antibody–Drug Conjugate Targeting of the Senescent Cell Marker Apolipoprotein D for Skin Rejuvenation

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(6), P. 5857 - 5857

Published: March 20, 2023

Senescent cells accumulate in aging skin, causing age-related changes and a decline functional efficiency. Therefore, senolysis, treatment that specifically removes senescent rejuvenates the should be explored. We targeted apolipoprotein D (ApoD), previously identified marker expressed on dermal fibroblasts, investigated novel senolysis approach using monoclonal antibody against this antigen secondary conjugated with cytotoxic drug pyrrolobenzodiazepine. Observations fluorescently labeled antibodies revealed ApoD functions as surface of is taken up internalized only by such cells. The concurrent administration PBD-conjugated eliminated without harming young antibody-drug conjugate mice combined reduced number dermis improved skin phenotype. These results provide proof-of-principle evaluation to eliminate conjugates cell proteins. This potential candidate for clinical applications treat pathological related diseases via removal

Language: Английский

---